Inulin

also known as Chicory root inulin · Fruitafit Inulin · Inulin and sodium chloride · Inulin component of iqp-ae-103

Developed for: bacterial infectious disease · classic or attenuated familial adenomatous polyposis · clear cell renal carcinoma · colorectal cancer · constipation disorder · iron deficiency anemia · latent autoimmune diabetes in adults · nosocomial infection
+6 more
· obesity disorder · osteoarthritis, knee · rheumatoid arthritis · sarcomatoid renal cell carcinoma · childhood onset asthma · cystic fibrosis
Investigated by: Assistance Publique - Hôpitaux de Paris · Columbia University · Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. · Dutch Cancer Society · Huazhong University of Science and Technology · Institut de Génétique Moléculaire de Montpellier
+15 more
· NIN Institute · National Center for Complementary and Integrative Health (NCCIH) · Radboud University Medical Center · Second Xiangya Hospital of Central South University · Technological Centre of Nutrition and Health, Spain · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · United States Department of Defense · Universidade de Passo Fundo · University Hospital, Montpellier · University of Michigan Rogel Cancer Center · University of Sydney · University of Veterinary and Animal Sciences, Lahore - Pakistan · VA Connecticut Healthcare System · Yale University · Yanqing Li

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	INULIN AND SODIUM CHLORIDE	—	1940-04-30	fda.gov ↗

Trials 13 · a red edge is where a trial was stopped

today

US approved 1940

NCT07189585 · Ph 2 NCT06866262 · Ph 1/2 NCT06347198 · Ph 0 NCT06738550 · not/applicable NCT04698330 · Ph 4 NCT05277090 · Ph 0 NCT04421313 · not/applicable NCT03865706 · Ph 2 NCT03894449 · Ph 1/2 NCT03630588 · Ph 2 NCT02794766 · Ph 2 NCT01588756 · Ph 1/2 NCT00319007 · Ph 2

1938193919401941194219431944194519461947194819491950195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT06347198	Apr → Dec 2024	colorectal cancer	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Unknown	No outcome recorded
Phase 0	NCT05277090	Mar 2022	—	Yanqing Li	Unknown	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT06866262	Aug 2025 → Aug 2031 expected	clear cell renal carcinoma, sarcomatoid renal cell carcinoma	University of Michigan Rogel Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT03894449	Apr → Jul 2019	iron deficiency anemia	University of Veterinary and Animal Sciences, Lahore - Pakistan	Completed	No outcome recorded
Phase 1/2	NCT01588756	Oct 2010 → May 2015	chronic kidney disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 25 trials
Phase 2	NCT07189585	Nov 2026 → Jul 2027 expected	osteoarthritis, knee	Yale University	Not yet recruiting	No outcome recorded
Phase 2	NCT03865706	Oct 2019 → Nov 2023	bacterial infectious disease, infectious disease with sepsis, nosocomial infection, nutritional disorder	Columbia University	Completed	No outcome recorded
Phase 2	NCT03630588	Aug → Dec 2018	obesity disorder	Technological Centre of Nutrition and Health, Spain	Completed	No outcome recorded
Phase 2	NCT02794766	Mar 2014 → May 2015	tongue disorder	Universidade de Passo Fundo	Completed	No outcome recorded
Phase 2	NCT00319007	Apr → Dec 2006	classic or attenuated familial adenomatous polyposis	Radboud University Medical Center	Unknown	No outcome recorded
Phase 41 trial
Phase 4	NCT04698330	May 2022 → Dec 2025 overdue	latent autoimmune diabetes in adults	Second Xiangya Hospital of Central South University	Not yet recruiting	No outcome recorded
Phase not applicable2 trials
—	NCT06738550	Mar 2023 → Jul 2024 overdue	chronic kidney disease, constipation disorder	NIN Institute	Enrolling by invitation	No outcome recorded
—	NCT04421313	Sep 2020 → Oct 2024	rheumatoid arthritis	University Hospital, Montpellier	Unknown	No outcome recorded

Also used as a comparator or background therapy in 3 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT06372249 Comparator	Nov 2025 → May 2027 expected	childhood onset asthma	Phoenix Children's Hospital	Recruiting	No outcome recorded
Phase 41 trial
Phase 4	NCT04118010 Comparator	Mar 2020 → Dec 2022	cystic fibrosis	Emory University	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT00431665 Background	Jul 1999 → Jun 2000	—	Medical University of Vienna	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	inulin	“A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.” NCT03894449 ↗ 15 “Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.” NCT03630588 ↗ “12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month.” NCT04421313 ↗ “agave inulin supplementation is provided 9 gr per day” NCT06738550 ↗ “Inulin” NCT06866262 ↗ NCT01588756 ↗ NCT04118010 ↗ NCT07189585 ↗ NCT03865706 ↗ NCT04698330 ↗ NCT02794766 ↗ NCT06347198 ↗ NCT05277090 ↗ NCT00319007 ↗ NCT00431665 ↗ NCT06372249 ↗
Known as	Chicory root inulin	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201646 ↗
Known as	Fruitafit Inulin	“Randomized controlled trial of soluble fiber (Fruitafit Inulin).” NCT06372249 ↗
Known as	Inulin and sodium chloride	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201646 ↗
Known as	Inulin component of iqp-ae-103	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201646 ↗
Modality	Other / unclassified	“Inulin (probiotic)” NCT00319007 ↗
Route	Intravenous	“AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less” NCT01588756 ↗